Patients with bilateral, synchronous, multiple subsolid pulmonary nodules (suspected multifocal primary lung cancers)
Conditions
Interventions
Control group:Sequential surgical treatment
Experimental group:Surgery combined with ablation therapy
Sponsors
The First Affiliated Hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Presence of bilateral multiple subsolid pulmonary nodules requiring intervention: Based on imaging and/or percutaneous biopsy, a multidisciplinary team (MDT) concludes that the patient has synchronous malignant or suspicious malignant subsolid nodules in both lungs, necessitating regional treatment for lesions on both sides. The maximum nodule diameter and the consolidation-to-tumor ratio (CTR) are used as the primary criteria to designate dominant and secondary lesions during MDT review. 2. Dominant subsolid lesion: maximum diameter 8 mm = 80 % of predicted value and FEV1/FVC>= 80 %. 7. Written informed consent obtained from the patient to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Solid malignant or suspicious malignant pulmonary nodules, or space-occupying lesions > 2 cm in maximum diameter. 2.Contralateral secondary lesions deemed unsuitable for sublobar resection or ablation. 3.Evidence of regional lymph-node or distant metastasis on pre-operative evaluation. 4. Suspected primary lung cancer with intrapulmonary metastasis. 5. Prior anti-tumor therapy (chemotherapy, radiotherapy, immunotherapy, targeted therapy, etc.). 6. Comorbid interstitial pneumonia, acute pulmonary infection, or pulmonary fibrosis. 7. Uncontrolled systemic diseases: refractory infection, severe cardiovascular/cerebrovascular disease, hepatic or renal dysfunction, diabetes mellitus, or other metabolic disorders. 8. History of prior malignancy. 9. Trauma or surgery within the preceding 6 months. 10. Pregnancy, planned pregnancy, or lactation. 11. Psychiatric or psychological disorders. 12. Any other condition considered by the investigators as unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-operative quality of life (QoL);5-year overall survival (OS) and overall survival time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor response to ablation;Treatment-related complications; | — |
Countries
China
Contacts
Public ContactXiangnan Li
The First Affiliated Hospital of Zhengzhou University
Outcome results
None listed